As Iconovo solidifies its product development and takes aim at a global market, a new analysis by Danske Bank indicates that the inhaler development company represents a significant market opportunity, thanks to its scalable business model in particular. The analysis values the company at 78-101 SEK per share – at least a 32 per cent increase from the current share price.
https://www.iconovo.se/wp-content/uploads/2020/02/inhalation-products-04222.jpg10001500Eva Norellhttps://www.iconovo.se/wp-content/uploads/2021/03/Breathtaking-innovation_Iconovo.pngEva Norell2020-04-21 11:21:132020-04-23 10:50:34Analysts see high value in Iconovo business
